Galera Therapeutics Reports Q1 2026 Financial Results, Faces Going Concern Risks

Galera Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.6 million, a slight increase from a net loss of $1.59 million in the same period of the previous year. The company’s operating expenses decreased to $1.66 million from $1.96 million year-over-year, primarily due to a significant reduction in research and development costs, which fell to $15,000 from $93,000. General and administrative expenses also decreased by $230,000 to $1.64 million, attributed to lower legal and professional fees. As of March 31, 2026, Galera had cash and cash equivalents of $5.5 million, down from $6.4 million at the end of 2025.

The company has undergone significant strategic changes, including the sale of its assets related to dismutase mimetics to Biossil, Inc. in October 2025 for an upfront payment of $3.5 million, with potential future payments of up to $105 million based on regulatory and commercial milestones. Following this divestiture, Galera has shifted its focus to a pan-inhibitor of nitric oxide synthase (NOS), which is currently in a Phase 1/2 trial for metaplastic breast cancer. Additionally, in April 2026, Galera entered into a merger agreement with Obsidian Therapeutics, which is expected to enhance its product pipeline and operational capabilities.

Operationally, Galera's employee headcount remains stable, with no significant changes reported. The company continues to manage its resources carefully, as it anticipates ongoing losses until it can generate significant revenue from its product candidates. The planned merger with Obsidian is contingent upon various conditions, including shareholder approval and the effectiveness of a registration statement with the SEC. The merger is expected to close in conjunction with a Private Investment in Public Equity (PIPE) financing of approximately $350 million, which is also subject to certain conditions.

Looking ahead, Galera's management has expressed concerns regarding its ability to continue as a going concern beyond the first quarter of 2027 without securing additional financing. The company plans to mitigate this risk through the anticipated merger with Obsidian and the associated PIPE financing. However, if these transactions do not proceed as planned, Galera may need to explore alternative strategies, including raising capital under potentially unfavorable terms or significantly reducing operations. The company’s future financial performance will largely depend on the successful development and commercialization of its product candidates.